Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

UC San Diego researchers reveal key differences in PD-1 checkpoint receptors between rodents and humans. Rodent PD-1 is ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface of ...

Januar 2025A team of Jülich scientists used a special RNA molecule to specifically attack and destroy glioblastoma cancer cells. The selectively ...

GXP-1 is under clinical development by Egret Therapeutics and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I drugs for Transplant Rejection have an 84% phase ...

Combining a premade SMN protein with a Spinraza-like drug (targets SMN2 gene) helped patient-derived motor neurons; potential ...

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...

Westlake University in China and the California Institute of Technology have designed a protein-based system ... to stay alive or undergo programmed cell death. Cells naturally process multiple ...

Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model ...